(Q38212081)

31 August 2017

title

B cells in MS and NMO: pathogenesis and therapy (English)

1 reference

31 August 2017

0 references

Markus Krumbholz

1

1 reference

31 August 2017

Edgar Meinl

series ordinal

2

1 reference

31 August 2017

language of work or name

1 reference

16 May 2014

1 reference

Seminars in Immunopathology

31 August 2017

published in

1 reference

31 August 2017

volume

36

1 reference

31 August 2017

issue

3

1 reference

31 August 2017

page(s)

339-350

1 reference

https://scigraph.springernature.com/pub.10.1007/s00281-014-0424-x

31 August 2017

exact match

0 references

cites work

Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Immunoadsorption in steroid-refractory multiple sclerosis: clinical experience in 60 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Complement-dependent pathogenicity of brain-specific antibodies in cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Intrastriatal injection of interleukin-1 beta triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Homogeneity of active demyelinating lesions in established multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Immunoglobulins and complement in postmortem multiple sclerosis tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

The who, how and where of antigen presentation to B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Follicular shuttling of marginal zone B cells facilitates antigen transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

B cell exchange across the blood-brain barrier in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Viability of autoantibody-targets: how to tackle pathogenetic heterogeneity as an obstacle for treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Antibody-independent B cell effector functions in relapsing remitting multiple sclerosis: clues to increased inflammatory and reduced regulatory B cell capacity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

B cells regulate autoimmunity by provision of IL-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Going both ways: immune regulation via CD1d-dependent NKT cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

IL-10 mediates resistance to adoptive transfer experimental autoimmune encephalomyelitis in MyD88(-/-) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Regulatory B cells in autoimmunity: developments and controversies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naïve/memory Breg ratio during a relapse but not in remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

IL-21 and CD40L synergistically promote plasma cell differentiation through upregulation of Blimp-1 in human B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Predominant autoantibody production by early human B cell precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

B-cell tolerance checkpoints in health and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Specific peripheral B cell tolerance defects in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

CSF IgG heavy-chain bias in patients at the time of a clinically isolated syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Expansion of CD27high plasmablasts in transverse myelitis patients that utilize VH4 and JH6 genes and undergo extensive somatic hypermutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

B cells and antibodies in multiple sclerosis pathogenesis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

VH usage and somatic hypermutation in peripheral blood B cells of patients with rheumatoid arthritis (RA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

The VH gene repertoire of splenic B cells and somatic hypermutation in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

A unique antibody gene signature is prevalent in the central nervous system of patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

The spectrum of MOG autoantibody-associated demyelinating diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Anti-aquaporin-1 autoantibodies in patients with neuromyelitis optica spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

The utility of cerebrospinal fluid analysis in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

BAFF controls neural cell survival through BAFF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Identification of BLyS (B lymphocyte stimulator), a non-myelin-associated protein, as a functional ligand for Nogo-66 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Atacicept: targeting B cells in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Aquaporin water channels in the nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

IgG glycan hydrolysis by EndoS inhibits experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

IL-6 increases B-cell IgG production in a feed-forward proinflammatory mechanism to skew hematopoiesis and elevate myeloid production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

The pro- and anti-inflammatory properties of the cytokine interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Interleukin-6 contributes to CNS axon regeneration upon inflammatory stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Soluble interleukin-6 (IL-6) receptor/IL-6 fusion protein enhances in vitro differentiation of purified rat oligodendroglial lineage cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Increased myelinating capacity of embryonic stem cell derived oligodendrocyte precursors after treatment by interleukin-6/soluble interleukin-6 receptor fusion protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Prevention of neuron and oligodendrocyte degeneration by interleukin-6 (IL-6) and IL-6 receptor/IL-6 fusion protein in organotypic hippocampal slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Exacerbation of experimental autoimmune encephalomyelitis by passive transfer of IgG antibodies from a multiple sclerosis patient responsive to immunoadsorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Antigen-specific interaction between T and B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Anti–Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Patients With Optic Neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-014-0424-X

Immusorba TR and Immusorba PH: basics of design and features of functions

21 January 2018

1 reference

12 December 2020

Protein array-based profiling of CSF identifies RBPJ as an autoantigen in multiple sclerosis

1 reference

12 December 2020

Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients

1 reference

12 December 2020

Cerebrospinal fluid IL-21 levels in Neuromyelitis Optica and multiple sclerosis

1 reference

12 December 2020

Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica

1 reference

12 December 2020

Ig lambda and heavy chain gene usage in early untreated systemic lupus erythematosus suggests intensive B cell stimulation.

1 reference

12 December 2020

Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse

1 reference

12 December 2020

Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination.

1 reference

12 December 2020

MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies

1 reference

12 December 2020

IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice.

1 reference

12 December 2020

Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).

1 reference

12 December 2020

IL-6 promotes regeneration and functional recovery after cortical spinal tract injury by reactivating intrinsic growth program of neurons and enhancing synapse formation

1 reference

12 December 2020

Biased usage of synovial immunoglobulin heavy chain variable region 4 by the anti-glucose-6-phosphate isomerase antibody in patients with rheumatoid arthritis.

1 reference

12 December 2020

Autoantibody biomarkers in childhood-acquired demyelinating syndromes: results from a national surveillance cohort.

1 reference

12 December 2020

Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange

1 reference

12 December 2020

Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab

1 reference

12 December 2020

Stimulation of myelin gene expression in vitro and of sciatic nerve remyelination by interleukin-6 receptor-interleukin-6 chimera

1 reference

12 December 2020

Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients

1 reference

12 December 2020

10.1007/S00281-014-0424-X

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

1025480823

0 references

1 reference